Trials / Completed
CompletedNCT01970930
Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
Treatment Strategies for Myeloproliferative Neoplasms by Targeting the Tumor Suppressor P53
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 131 (actual)
- Sponsor
- Icahn School of Medicine at Mount Sinai · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to isolate and characterize stem cells of patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) to find out why these cells are not working the way they should be and why they seem to be sensitive to regulatory factors in the blood, such as clotting.
Detailed description
Specific Aim 1: Assess the effects of RG7112 on MPN HSC/HPC p53 levels and study how it affects MPN stem cell function. Specific Aim 2. Assess the effects of a combination of low doses of IFNα and RG7112 on MPN HSC/HPC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Blood specimen | 4 green top tube 40 cc of blood draw |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2016-06-02
- Completion
- 2016-06-02
- First posted
- 2013-10-28
- Last updated
- 2018-01-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01970930. Inclusion in this directory is not an endorsement.